01Find both sides of the comparison

IUPHAR’s community guidelines define ligand bias relative to a reference ligand and a pair of pathways in a specified system. They distinguish ligand-dependent effects from differences created by the cellular system or the way the assays observe it.IUPHAR — Community guidelines for GPCR ligand bias, review 32 (opens in a new tab)

A claim that Peptide W favours Pathway A therefore prompts two questions: compared with which other pathway, and relative to which reference ligand? Without both answers, the statement’s meaning is incomplete.

Read the reference’s role rather than assuming it is universally balanced. The comparison can be useful even when it is a benchmark against a chosen compound, but the conclusion must preserve that benchmark.

Also distinguish the ligand used to define a maximum response from the ligand used as the bias reference. They may serve different analytical purposes in the report.

02Do not compare raw signal sizes across unlike assays

The raw test signal is ten times larger in A than in B, but the units and measurement scales differ. Relative to the displayed reference value, both are 80%. Neither the raw tenfold ratio nor these two percentages constitute a formal bias analysis.

The table lacks concentration-response curves, uncertainty and information about assay sensitivity. It is designed to expose a scale error, not to establish that the fictional ligand is biased or unbiased.

A quantitative method may incorporate potency, response magnitude and model assumptions. Check which method was used and whether the data support its parameters rather than selecting a convenient ratio from a figure.

03Check whether timing changes the apparent preference

Klein Herenbrink and colleagues’ 2016 dopamine D2 receptor study found that ligand-binding and signalling kinetics could substantially change apparent bias, including reversals for some comparisons over time. This is a specific experimental example of why timing belongs in a bias claim.Klein Herenbrink et al. — The role of kinetic context in apparent biased agonism at GPCRs (opens in a new tab)

Its result does not establish a bias profile for any peptide in this shop. It identifies a reading question: were the compared pathways observed at biologically and analytically appropriate times?

For a fictional Peptide W panel, imagine that A was measured near its early peak while B was measured after its signal had declined. The panel would need a timing-aware interpretation before the difference was assigned entirely to the ligand.

If a paper reports only one time point for each pathway, describe that boundary. Do not extrapolate the observed preference to every duration or cellular setting.

04Write the bias result with its conditions attached

A useful summary names the ligand, receptor, pathway pair, reference and system, then states the reported analysis and uncertainty. This gives readers a proposition they can compare with another study.

If studies disagree, first compare their references, constructs, cell backgrounds and timing. A different result may concern a different experimental comparison rather than a simple contradiction about the molecule.

Keep pathway preference separate from claims of greater safety or clinical benefit. Establishing a cellular bias pattern does not, by itself, establish how that pattern affects a person or a whole organism.

The goal is to preserve a potentially informative signalling distinction while avoiding a permanent good-pathway or bad-pathway label unsupported by the actual experiment.